Lifeward (NASDAQ:LFWD) Cut to “Strong Sell” at Zacks Research

Lifeward (NASDAQ:LFWD) was downgraded by Zacks Research from a “hold” rating to a “strong sell” rating in a research report issued on Wednesday,Zacks.com reports.

LFWD has been the subject of several other research reports. HC Wainwright increased their price target on Lifeward to $10.00 and gave the stock a “buy” rating in a research note on Thursday, March 19th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Lifeward in a report on Tuesday, April 21st. One investment analyst has rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Reduce” and a consensus price target of $10.00.

Lifeward Stock Performance

LFWD opened at $7.17 on Wednesday. The business’s 50 day moving average is $6.92 and its 200-day moving average is $7.08. The stock has a market cap of $20.18 million, a PE ratio of -0.36 and a beta of 0.36. The company has a current ratio of 2.40, a quick ratio of 1.82 and a debt-to-equity ratio of 1.16. Lifeward has a twelve month low of $4.14 and a twelve month high of $15.00.

Lifeward (NASDAQ:LFWD) last issued its quarterly earnings data on Friday, May 15th. The company reported ($6.70) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.18) by ($5.52). The business had revenue of $3.92 million during the quarter, compared to the consensus estimate of $5.78 million. Lifeward had a negative return on equity of 243.14% and a negative net margin of 123.66%. On average, analysts predict that Lifeward will post -4.27 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. HRT Financial LP boosted its position in shares of Lifeward by 149.7% during the 4th quarter. HRT Financial LP now owns 49,081 shares of the company’s stock valued at $28,000 after purchasing an additional 29,423 shares in the last quarter. Virtu Financial LLC boosted its holdings in Lifeward by 158.0% during the fourth quarter. Virtu Financial LLC now owns 60,474 shares of the company’s stock worth $35,000 after buying an additional 37,037 shares in the last quarter. Jane Street Group LLC grew its position in Lifeward by 77.3% in the fourth quarter. Jane Street Group LLC now owns 68,631 shares of the company’s stock worth $40,000 after buying an additional 29,927 shares during the last quarter. Finally, Citadel Advisors LLC increased its holdings in shares of Lifeward by 1,271.8% in the third quarter. Citadel Advisors LLC now owns 214,006 shares of the company’s stock valued at $152,000 after buying an additional 198,406 shares in the last quarter. 26.76% of the stock is owned by institutional investors and hedge funds.

Lifeward News Roundup

Here are the key news stories impacting Lifeward this week:

• Negative Sentiment: HC Wainwright cut Lifeward’s 2026 earnings outlook sharply, now expecting a much larger loss per share for FY2026 than previously forecast. Lifeward analyst estimates
• Negative Sentiment: The firm also reduced Q2 2026, Q3 2026, and Q4 2026 EPS estimates, suggesting weaker profitability in the near term. Lifeward analyst estimates
• Negative Sentiment: HC Wainwright lowered longer-term EPS projections for FY2027, FY2028, and FY2029 as well, indicating a slower path to earnings recovery. Lifeward analyst estimates
• Neutral Sentiment: Despite the lower estimates, HC Wainwright kept a Buy rating and a $10 price target on Lifeward, implying the firm still sees upside from current levels. Lifeward analyst estimates
• Positive Sentiment: HC Wainwright raised its FY2030 EPS estimate, suggesting the company could eventually return to stronger profitability over the long term. Lifeward analyst estimates

About Lifeward

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals post-stroke.